DIETARY SUPPLEMENT
The purpose of dietary supplements, is to enhance or supplement the diet. Even though a product is marketed as a dietary supplement, it is still considered a medicine to the extent that it is meant to treat, diagnose, cure, or prevent diseases.
Tablets, capsules, soft gels, powders, bars, gummies, and liquid supplements are just a few of the many different forms that supplements can take.
It is a product that is intended to supplement the diet that bears or contains one or more of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an amino acid.
A dietary substance use by human to supplement the diet by increasing the total daily intake, or a concentrate, metabolite, constituent, extract, or combinations of these ingredients.
FDA Role
Companies can often introduce a dietary supplement to the market without notifying FDA.
FDA’s role in regulating dietary supplements primarily begins after products enter the marketplace.
If a product is found to be unsafe or not otherwise in compliance with the law, FDA can work with the company to bring the product into compliance or possibly remove it from the market.
FDA regulates both finished dietary supplement products and dietary ingredients.
FDA regulates dietary supplements under a different set of regulations than those covering "conventional" foods (edible fruits and vegetables) and drug products.
Role of DSHEA
Manufacturers and distributors of dietary supplements and dietary ingredients are prohibited from marketing products that are adulterated or misbranded.
That means that these firms are responsible for evaluating the safety and labelling of their products before marketing to ensure that they meet all the requirements of the Federal Food, Drug, and Cosmetic Act (FFDCA) as amended by DSHEA and FDA regulations.
FDA has the authority to take action against any adulterated or misbranded dietary supplement product after it reaches the market
The Dietary Supplement Health and Education Act of 1994 was enacted to prohibit
Dietary supplement manufacturers and distributors from making false claims (such as "natural" and "therapeutic," on supplement labels)
The law also prohibits the manufacture and sale of adulterated dietary supplements.
Aim of these act:
To make dietary supplements safer by forbidding manufacturers and distributors from producing and selling mislabelled or adulterated products.
Act requires that the manufacturer of the dietary supplement ensures their product meets DSHEA and FDA regulations.
Table of Contents
Short Title Reference Table Of Contents
Findings
Definitions
Safety of Dietary Supplements and Burden of Proof on FDA
Dietary Supplement Claims
Statements of Nutritional Support
Dietary supplement ingredient labeling and nutrition information labeling
New dietary ingredients
Good manufacturing practices
Conforming amendments
Withdrawal of the regulations and notice
Commission on dietary supplement labels
NSF certification, Standard for dietary supplementAtul Bhombe
Manufacturers, regulators and consumers look to NSF International for the development of public health standards and certification programs that help protect the world’s food, water, consumer products and environment. NSF is a global, independent organization, our standards team facilitates development of public health standards, and our service teams test, audit and certify products and services
REGULATORY ASPECTS OF FOOD & NUTRACEUTICALS A GLOBALKapilKumar198
This presentation contains detailed information about the regulatory aspects of food and nutraceuticals a global prospective, which includes WHO guidelines on nutrition and NSF International.
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...Swapnil Fernandes
- Nutraceutical market has shown steady increase in the last decade.
- The import, manufacture and marketing regulations for nutraceuticals in India have been streamlined with the updation of the FSSAI regulations 2016.
- RDA’s are a collection of values to express a person's nutrient need based on their life stage & gender.
- The RDA recommendations for the Indian population has been provided by the ICMR on the basis of scientific studies and subsequent data generated.
Herbal products, also known as botanical products or phytomedicines, are products made from plants to treat diseases or maintain health.
Herbal products are made by extracting active ingredients from plant parts, such as leaves, bark, roots, seeds, or flowers.
Herbal products, including dietary supplements, are regulated by the FDA. However, unlike pharmaceutical drugs, they do not require pre-market approval. Instead, manufacturers are responsible for ensuring the quality and safety of their products.
The FDA establishes Good Manufacturing Practices (GMP) regulations for dietary supplements to ensure quality control during manufacturing.
The safety of herbal products in the USA is overseen by various regulatory agencies, primarily the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC).
To ensure a high degree of safety and effectiveness of herbal products and quality control standards during the manufacturing of herbal supplements and medicines, AHPA published GACP (Good Agriculture and Collection Practices) guideline in the American Herbal Pharmacopoeia.
NSF certification, Standard for dietary supplementAtul Bhombe
Manufacturers, regulators and consumers look to NSF International for the development of public health standards and certification programs that help protect the world’s food, water, consumer products and environment. NSF is a global, independent organization, our standards team facilitates development of public health standards, and our service teams test, audit and certify products and services
REGULATORY ASPECTS OF FOOD & NUTRACEUTICALS A GLOBALKapilKumar198
This presentation contains detailed information about the regulatory aspects of food and nutraceuticals a global prospective, which includes WHO guidelines on nutrition and NSF International.
NSF International and its role in Dietary supplements & Nutraceutical industr...SyedArshiya4
This presentation will allow the reader to know about NSF international its history, mission, NSF Mark, role in Dietary supplements and Nutraceutical industries. It also give information on testing, inspection, certification of products.
FSSAI REGULATIONS FOR THE IMPORT, MANUFACTURE AND SALE OF NUTRACEUTICALS IN I...Swapnil Fernandes
- Nutraceutical market has shown steady increase in the last decade.
- The import, manufacture and marketing regulations for nutraceuticals in India have been streamlined with the updation of the FSSAI regulations 2016.
- RDA’s are a collection of values to express a person's nutrient need based on their life stage & gender.
- The RDA recommendations for the Indian population has been provided by the ICMR on the basis of scientific studies and subsequent data generated.
Herbal products, also known as botanical products or phytomedicines, are products made from plants to treat diseases or maintain health.
Herbal products are made by extracting active ingredients from plant parts, such as leaves, bark, roots, seeds, or flowers.
Herbal products, including dietary supplements, are regulated by the FDA. However, unlike pharmaceutical drugs, they do not require pre-market approval. Instead, manufacturers are responsible for ensuring the quality and safety of their products.
The FDA establishes Good Manufacturing Practices (GMP) regulations for dietary supplements to ensure quality control during manufacturing.
The safety of herbal products in the USA is overseen by various regulatory agencies, primarily the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC).
To ensure a high degree of safety and effectiveness of herbal products and quality control standards during the manufacturing of herbal supplements and medicines, AHPA published GACP (Good Agriculture and Collection Practices) guideline in the American Herbal Pharmacopoeia.
It contains details rules and regulations /legislation of Pharmaceuticals, Cosmetics, Active Substance Masters File, Investigational Medicinal Product Dossier for European Union
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
plasma master file in European countries and requirements in letter of intent...Sanjay batra
it includes that what is plasma master file, principles, procedure to file PMF, strategy involved, administration information, certification procedure & inspection
The recently enacted Food Safety Modernization Act is the greatest expansion of FDA’s food regulatory authority since the enactment in 1938 of the Federal Food, Drug, and Cosmetic Act. This presentation discuses the scope, impact and implementation of the Act. Presented by FDAImports.com Founder and CEO, Benjamin England.
For more on the Food Safety Modernization Act and how it affects companies, manufacturers and importers please visit:
http://www.fdaimports.com/FSMA
Food Safety Modernization Act (FSMA) regulatory requirements by FDABrian Thomas
Food Safety Modernization Act (FSMA) is placing new regulatory demands on food manufacturers and suppliers in the US market. For the first time, FDA has a legislative mandate to require comprehensive, prevention-based controls across the food supply. As key implementation deadlines approach, food manufacturers are shifting from a reactionary to a preventive footing, with stricter controls, documentation, and supplier verification requirements. This means there is a new regulatory world for food producers, including regulations for food-borne illness prevention and traceability. Presentation provides a summary of the new regulations, the risks and challenges faced by food producers, and the opportunities to take action through applications of modern control and information technology.
GMP Guidelines for Nutraceuticals - Indian And EuropeanVarshaJindaniya
This GMP Guidance Document covers the entire manufacturing process of Health Supplements/ Nutraceuticals in the form of Powders, Tablets, Capsules, Soft Gel Capsules and Liquids starting from procurement of raw materials to despatch of finished product.
Contact me: www.linkedin.com/in/varsha-jindaniya
Biosimilars
A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). (A medicine whose active substance is made by a living organism.)
Biologicals
Biological medicines contain active substances from a biological source, such as living cells or organisms and are often produced by cutting-edge technology.
Biological medicinal product
Biological Medicinal Products, also known as biologics or biologicals, are medicinal products that are manufactured using biotechnology processes and derived from living organisms or their products. They can include vaccines, blood products, gene therapies, monoclonal antibodies, recombinant proteins, and other complex biological substances.
Biological Investigational Medicinal Product
Refer to biological products that are being investigated in clinical trials or research studies to evaluate their safety, efficacy, or pharmacokinetic properties. These products have not yet received marketing authorization and are still in the experimental phase.
In the European Union, A biological substance is referred as the active ingredient in biological products.
A "biological substance" is defined as "a substance that is produced by or extracted from a biological source
That requires a combination of physico-chemical-biological testing, along with the production process and its control, for its characterization and the determination of its quality.“
Examples: Immunologic medicines
Medicines derived from human blood and plasma
Medicines developed by means of recombinant DNA technology
Hybridoma and mAb methods
Advanced therapy medicinal products
The requirements of the EU centralized procedure.
The approval standards for biotechnology products are the same as for chemically synthesized medicines.
Both types of products must be safe and effective and have appropriate quality.
MAA for a biotechnology product must meet the standard dossier submission requirements
MAA must generally comply with the CTD format, including with respect to
Module I (administrative information, including labelling)
Module 2 (various summaries)
Module 3 (chemical, pharmaceutical, and biological information)
Module 4 (nonclinical reports)
Module 5 (clinical study reports)
The EU has approved the highest number of biosimilars worldwide, and consequently has the most extensive experience of their use and safety.
EMA has issued scientific guidelines to help developers conform to the strict regulatory requirements for approving biosimilars.
The guidelines have evolved to keep pace with rapid advances in biotechnology and analytical sciences, and they take on board increasing experience of clinical use.
All medicines produced using biotechnology and those for specific indications must be approved in the EU through EMA
Some biosimilars may be approved at national level, such as some low-molecular weight heparins derived from porcine intestinal mucosa.
GCC countries, Drug registration regulations of Saudi Arabia, Medicinal Product Registration process (SA), Drug Registration Requirement (SA), Post Registration Requirements in (SA), Drug registration regulations UAE Medicinal Product Registration process (UAE), Drug Registration Requirement (UAE).
Since 2003, The Saudi Food and Drug Authority (SFDA) is the competent authority for registrations, maintenance, quality, pharmacovigilance and import of medicinal products.
SFDA is responsible for handling and licensing the manufacture, import, export, distribution, promotion, and advertising of medicinal products.
The SFDA is also responsible for assessing the safety, efficacy, and quality of medicinal products, issuing marketing authorizations, and monitoring the quality & safety of the marketed medicinal products.
SFDA prefers the drug dossier submission in electronic format (eCTD).
It is an independent authority from the Ministry of Health.
Market Authorization
The process of submitting a new Marketing Authorization Application (MAA) consists of the following phases:
Phase 1
Step 1: Online Registration on the Drug Establishments National Registry (DENR)
The applicant register online on the DENR to get a username and password, which enables the applicant to log in and avail all the electronic services of the drug sector.
Step 2: Marketing Authorization Application (MAA) Submission:
The applicant shall apply through the Saudi Drug Registration (SDR) system to fill out the application form and pay the fees.
Upload the eCTD file to the system through the SDR system portal.
A soft copy of the eCTD should be submitted labelled as per the SFDA guideline, along with the hard copies of the original documents.
Phase 2
Step 1: Validation
The product file will be validated on technical and business bases to ensure that the applicant fulfils the requirement.
Step 2 - Assessment, Testing and Inspection
The relevant departments will evaluate the MAA to assess quality, safety, and efficacy, along with the onsite GMP inspection and sample analysis by the SFDA central laboratories.
Step 3 - Pricing
The Pricing Department will review the product’s price according to the “SFDA's pricing rules.”
Step 4 - Product Licensing
The Registration Committee will review the registration request for approval.
Verification and Abridged Procedure
Verification Process
This process will be applicable if the product has been approved and marketed by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA).
For all pharmaceutical items, even those that are not intended to be used as medicines, such as nutritional supplements and cosmetics, to be registered with the Ministry of Health & Prevention (MOHAP) in the United Arab Emirates.
The UAE government takes all necessary measures to ensure that safety standards and procedures are followed in cases of import, export, trade, and sale of products, which are consumed or used by the people.
Regulatory requirements for orphan drugs delivery, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgavi/Belgaum, Karnataka, India.
It contains details rules and regulations /legislation of Pharmaceuticals, Cosmetics, Active Substance Masters File, Investigational Medicinal Product Dossier for European Union
MARKETING AUTHORISATION, LICENSING AND QUALITY ASSESSMENT OF VACCINES IN INDI...Swapnil Fernandes
- European pharmaceutical legislation provides a comprehensive framework for the marketing authorisation of vaccines.
- In contrast to the European scenario, the Indian scenario for vaccines is relatively less regulated and follows the same process of approval as other biologics in spite of having a National Handbook for Vaccine Policy.
- Vaccine authorisation in the US, as is the case in EU, is a more straightforward process than in most other markets as the USFDA has provided vaccines with a distinct set of regulations in concerned areas of safety and quality.
plasma master file in European countries and requirements in letter of intent...Sanjay batra
it includes that what is plasma master file, principles, procedure to file PMF, strategy involved, administration information, certification procedure & inspection
The recently enacted Food Safety Modernization Act is the greatest expansion of FDA’s food regulatory authority since the enactment in 1938 of the Federal Food, Drug, and Cosmetic Act. This presentation discuses the scope, impact and implementation of the Act. Presented by FDAImports.com Founder and CEO, Benjamin England.
For more on the Food Safety Modernization Act and how it affects companies, manufacturers and importers please visit:
http://www.fdaimports.com/FSMA
Food Safety Modernization Act (FSMA) regulatory requirements by FDABrian Thomas
Food Safety Modernization Act (FSMA) is placing new regulatory demands on food manufacturers and suppliers in the US market. For the first time, FDA has a legislative mandate to require comprehensive, prevention-based controls across the food supply. As key implementation deadlines approach, food manufacturers are shifting from a reactionary to a preventive footing, with stricter controls, documentation, and supplier verification requirements. This means there is a new regulatory world for food producers, including regulations for food-borne illness prevention and traceability. Presentation provides a summary of the new regulations, the risks and challenges faced by food producers, and the opportunities to take action through applications of modern control and information technology.
GMP Guidelines for Nutraceuticals - Indian And EuropeanVarshaJindaniya
This GMP Guidance Document covers the entire manufacturing process of Health Supplements/ Nutraceuticals in the form of Powders, Tablets, Capsules, Soft Gel Capsules and Liquids starting from procurement of raw materials to despatch of finished product.
Contact me: www.linkedin.com/in/varsha-jindaniya
Biosimilars
A biosimilar is a biological medicine highly similar to another already approved biological medicine (the 'reference medicine'). (A medicine whose active substance is made by a living organism.)
Biologicals
Biological medicines contain active substances from a biological source, such as living cells or organisms and are often produced by cutting-edge technology.
Biological medicinal product
Biological Medicinal Products, also known as biologics or biologicals, are medicinal products that are manufactured using biotechnology processes and derived from living organisms or their products. They can include vaccines, blood products, gene therapies, monoclonal antibodies, recombinant proteins, and other complex biological substances.
Biological Investigational Medicinal Product
Refer to biological products that are being investigated in clinical trials or research studies to evaluate their safety, efficacy, or pharmacokinetic properties. These products have not yet received marketing authorization and are still in the experimental phase.
In the European Union, A biological substance is referred as the active ingredient in biological products.
A "biological substance" is defined as "a substance that is produced by or extracted from a biological source
That requires a combination of physico-chemical-biological testing, along with the production process and its control, for its characterization and the determination of its quality.“
Examples: Immunologic medicines
Medicines derived from human blood and plasma
Medicines developed by means of recombinant DNA technology
Hybridoma and mAb methods
Advanced therapy medicinal products
The requirements of the EU centralized procedure.
The approval standards for biotechnology products are the same as for chemically synthesized medicines.
Both types of products must be safe and effective and have appropriate quality.
MAA for a biotechnology product must meet the standard dossier submission requirements
MAA must generally comply with the CTD format, including with respect to
Module I (administrative information, including labelling)
Module 2 (various summaries)
Module 3 (chemical, pharmaceutical, and biological information)
Module 4 (nonclinical reports)
Module 5 (clinical study reports)
The EU has approved the highest number of biosimilars worldwide, and consequently has the most extensive experience of their use and safety.
EMA has issued scientific guidelines to help developers conform to the strict regulatory requirements for approving biosimilars.
The guidelines have evolved to keep pace with rapid advances in biotechnology and analytical sciences, and they take on board increasing experience of clinical use.
All medicines produced using biotechnology and those for specific indications must be approved in the EU through EMA
Some biosimilars may be approved at national level, such as some low-molecular weight heparins derived from porcine intestinal mucosa.
GCC countries, Drug registration regulations of Saudi Arabia, Medicinal Product Registration process (SA), Drug Registration Requirement (SA), Post Registration Requirements in (SA), Drug registration regulations UAE Medicinal Product Registration process (UAE), Drug Registration Requirement (UAE).
Since 2003, The Saudi Food and Drug Authority (SFDA) is the competent authority for registrations, maintenance, quality, pharmacovigilance and import of medicinal products.
SFDA is responsible for handling and licensing the manufacture, import, export, distribution, promotion, and advertising of medicinal products.
The SFDA is also responsible for assessing the safety, efficacy, and quality of medicinal products, issuing marketing authorizations, and monitoring the quality & safety of the marketed medicinal products.
SFDA prefers the drug dossier submission in electronic format (eCTD).
It is an independent authority from the Ministry of Health.
Market Authorization
The process of submitting a new Marketing Authorization Application (MAA) consists of the following phases:
Phase 1
Step 1: Online Registration on the Drug Establishments National Registry (DENR)
The applicant register online on the DENR to get a username and password, which enables the applicant to log in and avail all the electronic services of the drug sector.
Step 2: Marketing Authorization Application (MAA) Submission:
The applicant shall apply through the Saudi Drug Registration (SDR) system to fill out the application form and pay the fees.
Upload the eCTD file to the system through the SDR system portal.
A soft copy of the eCTD should be submitted labelled as per the SFDA guideline, along with the hard copies of the original documents.
Phase 2
Step 1: Validation
The product file will be validated on technical and business bases to ensure that the applicant fulfils the requirement.
Step 2 - Assessment, Testing and Inspection
The relevant departments will evaluate the MAA to assess quality, safety, and efficacy, along with the onsite GMP inspection and sample analysis by the SFDA central laboratories.
Step 3 - Pricing
The Pricing Department will review the product’s price according to the “SFDA's pricing rules.”
Step 4 - Product Licensing
The Registration Committee will review the registration request for approval.
Verification and Abridged Procedure
Verification Process
This process will be applicable if the product has been approved and marketed by both the European Medicines Agency (EMA) and the United States Food and Drug Administration (USFDA).
For all pharmaceutical items, even those that are not intended to be used as medicines, such as nutritional supplements and cosmetics, to be registered with the Ministry of Health & Prevention (MOHAP) in the United Arab Emirates.
The UAE government takes all necessary measures to ensure that safety standards and procedures are followed in cases of import, export, trade, and sale of products, which are consumed or used by the people.
Regulatory requirements for orphan drugs delivery, Prof. Dr. Basavaraj K. Nanjwade, KLE University College of Pharmacy, Belgavi/Belgaum, Karnataka, India.
In our post about the nutraceuticals industry, dietary supplements as a category of nutraceuticals are subject to compliance with FDA regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA).
In our post about the nutraceuticals industry, dietary supplements as a category of nutraceuticals are subject to compliance with FDA regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA).
In our post about the nutraceuticals industry, dietary supplements as a category of nutraceuticals are subject to compliance with FDA regulations under the Dietary Supplement Health and Education Act of 1994 (DSHEA).
Cascadia Cucumber 1.2: The significance of properly marketing & labeling diet...Cascadia Capital
The Cascadia Cucumber is a quarterly newsletter written by Cascadia Capital’s Health and Wellness group that outlines interesting subjects and up-and-coming products in the sector. Our goal is to provide the reader with insightful information regarding trending topics and recent transactions within the Health and Wellness space.
Presentation to the San Diego Regulatory Affairs Network (SDRAN) RAC Review course; August 2011; covering:
♦ Basics
♦ New Dietary Ingredients
♦ Claims Allowed
♦ GMPs and Other Regulatory Requirements
♦ Adverse Events
As defined by Congress in the Dietary Supplement Health and Education Act, which became
law in 1994, adietary supplement is a product (other than tobacco) that
-- is intended to supplement the diet;
-- contains one or more dietary ingredients
(including vitamins; minerals; herbs or
other botanicals; amino
acids; and other substances) or their constituents;
-- is intended to be taken by mouth as a pill, capsule,
tablet, or liquid; and
-- is labeled on
the front panel as being a dietary supplement.
http://ods.od.nih.gov/
Introduction
Definition
Classification
Regulatory registration procedure
Quality system requirements
Clinical evaluation
Investigation of medical devices
Summary
Medical devices are regulated by the National Medical Product Administration (NMPA), formerly the China Food and Drug Administration (CFDA)
Manufacturers must register their devices with the NMPA before selling or distributing in China.
The NMPA reviews all device applications and has strict requirements for submission documentation, testing, and clinical data.
Any instrument, apparatus, appliance, material, or other article whether used alone or in combination, including the software necessary for its proper application.
Diagnosis, prevention, monitoring, treatment or alleviation of disease
Diagnosis, monitoring, treatment, alleviation of compensation for an injury or handicap conditions
Investigation, replacement or modification for anatomy or a physiological process
Control of conception
The Chinese authorities (CFDA/NMPA) have their own quality management system requirements.
However, these “GMP requirements” are very similar to ISO 13485.
Therefore, manufacturers usually submit the ISO 13485 certificate.
However, the audit will review this certificate against the Chinese GMP requirements.
These audits are regularly carried out during the approval procedure and/or after a recall.
NMPA issued and implemented the "Guideline on Inspection of Quality Management System for Medical Device Registration" on October 10, 2022.
Product Life-cycle Process
The guideline specifies the basic requirements for registration inspection, self-inspection, commissioned inspection, and extended inspection, etc. Applicant needs to:
Ensure the design, development, production, and other process data to be true, accurate, complete, and traceable, and consistent with the registration application materials.
Carry out the registration QMS inspection in reference to the registration application materials, and focus on the design, development, procurement, production management, and quality control of the product.
For lower-risk medical devices (Class I and Class II), clinical evaluation may not always be required. However, higher-risk devices (Class III and implantable devices) generally require clinical evaluation.
The evaluation involves reviewing existing clinical data, scientific literature, and relevant clinical research to assess the safety and performance of the device.
All clinical trials for medical devices must follow China Good Clinical Practices
Clinical investigations are required if no equivalent devices can be found and safety and efficacy cannot be proven with other clinical and non-clinical data.
For certain medical devices, the NMPA may require clinical investigations, especially for novel devices or those with significant risk.
Clinical investigations involve conducting studies on human subjects to generate clinical data on the safety and effectiveness of the device.
Patents are a type of techno-legal document that describes novel, unique, and industrially applicable inventions. A request for the issuance of a patent for an invention created and detailed in the patent specification is known as a patent application.
a) Novelty: Before submitting the patent application in India, the subject matter specified in the specification was not published in India or anywhere else.
b) Inventive Step: A person who is experienced in the art would not recognize the invention in light of the earlier publication, knowledge, or document.
c) Industrial Applicability: In order to be produced or used in the industry, an invention must have some sort of utility.
DOCUMENTS REQUIRED FOR PATENT REGISTRATION:
1. (Form 1) Application form for the grant of patent in India.
2. (Form 2) If a provisional specification is submitted, it must be followed within a year by a complete specification. Provisional or complete specification of patent in duplicate.
3. (Form 3) Information and undertaking listing each foreign patent application's number, filing date, and current status in duplicate.
4. Priority document (if the priority date is claimed) in convention application, when directed by the Controller
5. (Form 5) When a complete specification follows a provisional specification, or in the event of a convention or PCT national phase application, an inventor declares their invention
ADVANTAGES OF REGISTERING A PATENT
1. A patent serves as a means of supporting innovations and inventions. The invention or concept belongs to the applicant after they receive the patent.
2. A business must register for a patent because a patent prevents competitors from stealing, selling, or importing the intellectual property without authorization.
3. In support of the current legislation, the patent holder can thereby defend his patent rights.
a) Like other types of property, patents can be bought, sold, or licensed.
b) Ownership of the patent may also be transferred by the inventor.
c) A patented product enhances brand recognition and can allow the company to charge more.
d) With exclusive patent rights, the inventor has long-term control over how the innovation is used.
e) Under the International Patent Protection Scheme, the government would cover up to Rs. 15 lakhs (or 50% of the total cost) of an MSME's international patent filing.
TRADEMARK: 1. A trademark is a symbol that can be used to separate the products or services of one company from those of other companies. Intellectual property rights provide protection for trademarks.
2. A trademark registration grants the owner of the trademark the sole right to use it. This suggests that the trademark may be used solely by its owner or may be licensed to a third party for use in exchange for payment.
COPYRIGHT: 1. The legal term "copyright" (sometimes known as "author's right") is used to refer to the ownership rights that authors and other artists have over their creative works.
DOCUMENT
A DOCUMENT is a piece of written, printed, or electronic matter that provides information or evidence or that serves as an official record.
WHY DOCUMENTATION
Documents and products are produced in pharmaceuticals but regulatory bodies are interested to see documents first.
Due to the importance given to documentation in pharma "good documentation practices" is required.
Good documentation is a systematic procedure of preparation, checking, verifying, issuing, storing and reviewing of any documents.
Clearly written documents prevent errors of various activities in Pharma.
PURPOSE OF DOCUMENTATION:
Defines specifications and procedures for all materials and methods of manufacture and control.
Ensures that all personnel knows what to do and when to do it.
Ensure that authorized persons have all information necessary for release of product.
Ensures documented evidence, traceability, provide records and audit trail for investigation.
Ensures availability of data for validation, review and statistical analysis.
Drug substance :
Drug substance is an active ingredient that is intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or any function of the human body, but does not include intermediates used in the synthesis of such ingredient.
Drug product :
Drug product is a finished dosage form, e.g., tablet, capsule, or solution, that contains a drug substance, generally, but not necessarily, in association with one or more other ingredients.
Exploratory Product Development Brief
Many companies today utilize some form of a traditional phased-and-gated product development process, which originated more than 50 years ago. It hasn’t changed substantially since then.
A phased-and-gated system creates multiple batches that slows down the overall speed of a product development project.
When companies try to maintain a traditional phased- and-gated process in a changing environment, the product development team is unable to manage to the scope, timeline and budget approved at the outset.
The result usually includes changing product requirements, unexpected problems, rework, schedule delays, breaking the budget and commercial failure.
GOAL
Develop Exploratory PD® (ExPD), which help companies achieve growth and improve product development success through an adaptive system.
The primary goal of ExPD is to reduce uncertainty and risk by reducing the unknown.
When organizations adapt quickly to the changing environment (market, technology, regulations, globalization, etc.), they reduce uncertainty and risk leading to product success.
APPROACH
The product development team needs an approach that allows them to adapt to change in customer needs, markets, competition, technology and more.
ExPD proposes a new approach to developing products, using a two-pronged solution:
1) Treating product development from a comprehensive systems perspective
Animal Testing: Rationale for conducting studies, CPCSEA Guidelines
The use of animals in research is currently an essential component of the drug discovery process.
Animals help us advance our scientific understanding, serve as models to study disease, help us develop and test potential new medicines and therapies.
Animal testing has benefited researchers in understanding how to treat and prevent various conditions such as high blood pressure, diabetes, tuberculosis, polio, muscular dystrophy, and Parkinson's disease.
Education:
Undergraduate teaching to demonstrate effects of various drugs although this has been phased out in most institutes.
Postgraduate teaching to demonstrate the effects of various drugs, to determine the nature of an unknown drug for bioassay, screening methods and to learn skills e.g. administering drugs.
Research:
A larger number and a greater variety of animals are used in pure research than in applied research. This usually involves studies on embryogenesis, developmental biology, behaviour and breeding in Fruit flies, nematodes, mice and rats.
INTRODUCTION
The motto of Prevention of Cruelty to Animals (PCA) Act 1960 as amended in 1982 is to prevent infliction of unnecessary pain or suffering on animals.
The Central Government has constituted a Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), which is duty bound to take all such measures as may be necessary to ensure that animals are not subjected to unnecessary pain or suffering before, during or after the performance of experiments on them.
The goal of these guidelines is to promote the human care of animal used in biomedical and behavioural research and testing.
To avoid/minimize pain and suffering inflicted on experimental animals
Inspection of animal house facilities
It provides guidelines for -
Proper care, housing, breeding, maintenance, handling and use of experimental animals.
Source of experimental animals
Acceptable experimental procedures for anaesthesia and euthanasia.
Registration of establishments conducting animal experimentation or breeding of animals for this purpose.
Selection and assignment of nominees for the Institutional Animal Ethics Committees (IAEC) of the registered establishments.
Approval of Animal House Facilities on the basis of reports of inspections conducted by CPCSEA.
Permission for conducting experiments involving use of animals.
Recommendation for import of animals for use in experiments.
Action against establishments in case of established violation of any legal norm/stipulation.
Conduct of Training Programmes for the Nominees of CPCSEA.
Conduct/Support of Conference/Workshop on Animal Ethics.
To assure quality maintenance and safety of animals used in laboratory studies while conducting biomedical and behavioural research and testing of products.
Quarantine
2. Personal hygiene
3. Environment
4. Physical facility
5. Animal husbandry
6. Animal disposal
7. Documentation
Requirements And Guidelines For Permission To Import / or Manufacture of New Drugs For Sale or To Undertake Clinical Trials
Schedule Y was introduced under the Drugs and Cosmetics Act 1940, to
introduce requirements for countries to get permission for:
Importing
Manufacturing new drugs
Conducting Clinical Trials.
Application for permission
Clinical Trial
Studies in specific population
Post marketing surveillance
Special studies: BA/BE studies
This presentation contain introduction to Good Distribution Practices Guideline. and Legal GDP requirements put worldwide.
Good distribution practice (GDP) describes the minimum standards that a wholesale distributor must meet to ensure that the quality and integrity of medicines is maintained throughout the supply chain
Each participant in the distribution chain must agree by the relevant requirements in order to retain the original quality of pharmaceutical products.
Each activity in the distribution of pharmaceutical products shall be carried out according to the principles of Good Distribution Practices (GDP) as applicable.
The risks involved are likely to be of a nature comparable to those that are present in the industrial environment, such as mix-ups, adulteration, contamination, cross-contamination, and spurious.
The guideline addresses
Personnel
Quality System
Premises Warehousing and Storage
Documentation
Traceability
Complaints and Returns
Transportation
How to Split Bills in the Odoo 17 POS ModuleCeline George
Bills have a main role in point of sale procedure. It will help to track sales, handling payments and giving receipts to customers. Bill splitting also has an important role in POS. For example, If some friends come together for dinner and if they want to divide the bill then it is possible by POS bill splitting. This slide will show how to split bills in odoo 17 POS.
The Art Pastor's Guide to Sabbath | Steve ThomasonSteve Thomason
What is the purpose of the Sabbath Law in the Torah. It is interesting to compare how the context of the law shifts from Exodus to Deuteronomy. Who gets to rest, and why?
Instructions for Submissions thorugh G- Classroom.pptxJheel Barad
This presentation provides a briefing on how to upload submissions and documents in Google Classroom. It was prepared as part of an orientation for new Sainik School in-service teacher trainees. As a training officer, my goal is to ensure that you are comfortable and proficient with this essential tool for managing assignments and fostering student engagement.
Unit 8 - Information and Communication Technology (Paper I).pdfThiyagu K
This slides describes the basic concepts of ICT, basics of Email, Emerging Technology and Digital Initiatives in Education. This presentations aligns with the UGC Paper I syllabus.
This is a presentation by Dada Robert in a Your Skill Boost masterclass organised by the Excellence Foundation for South Sudan (EFSS) on Saturday, the 25th and Sunday, the 26th of May 2024.
He discussed the concept of quality improvement, emphasizing its applicability to various aspects of life, including personal, project, and program improvements. He defined quality as doing the right thing at the right time in the right way to achieve the best possible results and discussed the concept of the "gap" between what we know and what we do, and how this gap represents the areas we need to improve. He explained the scientific approach to quality improvement, which involves systematic performance analysis, testing and learning, and implementing change ideas. He also highlighted the importance of client focus and a team approach to quality improvement.
2. CONTENTS
• Introduction to Dietary Supplements
• Classification of Dietary Supplements
• Benefits of Dietary Supplements
• DSHEA 1994
Table of Contents
1. Short Title Reference Table Of Contents
2. Findings
3. Definitions
4. Safety of Dietary Supplements and Burden of
Proof on FDA
5. Dietary Supplement Claims
6. Statements of Nutritional Support
Presentation Title: Dietary Supplement Health and Education Act of 1994 2
3. Conti...
7. Dietary supplement ingredient labeling and nutrition information labeling
8. New dietary ingredients
9. Good manufacturing practices
10. Conforming amendments
11. Withdrawal of the regulations and notice
12. Commission on dietary supplement labels
13. Office of dietary supplements
Presentation Title: Dietary Supplement Health and Education Act of 1994 3
4. INTRODUCTION
DIETARY SUPPLEMENT
The purpose of dietary supplements, is to enhance or supplement the diet. Even though a
product is marketed as a dietary supplement, it is still considered a medicine to the
extent that it is meant to treat, diagnose, cure, or prevent diseases.
Tablets, capsules, soft gels, powders, bars, gummies, and liquid supplements are just a
few of the many different forms that supplements can take.
It is a product that is intended to supplement the diet that bears or contains one or more
of the following dietary ingredients: a vitamin, a mineral, an herb or other botanical, an
amino acid.
A dietary substance use by human to supplement the diet by increasing the total daily
intake, or a concentrate, metabolite, constituent, extract, or combinations of these
ingredients.
Presentation Title: Dietary Supplement Health and Education Act of 1994 4
5. Common supplements
include:
Vitamins (such as multivitamins or individual vitamins like vitaminD
and biotin)
Minerals (such as calcium, magnesium, and iron)
Botanicals or herbs (such as echinacea and ginger)
Botanical compounds (such as caffeine and curcumin)
Amino acids (such as tryptophan and glutamine)
Live microbials (commonly referred to as “probiotics”)
Presentation Title: Dietary Supplement Health and Education Act of 1994 5
6. Classification of supplements, examples and contents
Class Example Contents
Activator Amino acids Growth hormone
Carbohydrate Dextrose Contain vitamins and electrolytes
Food and Food stuff Fish oils, mineral and vitamins Contain garlic, kelp, royal jelly, yeast
Herbs Ginseng, Fiber Contains amino acids, plant Source
Minerals Selenium, multi-mineral tablets Contains only minerals
Multivitamins and
multiminerals
Vitamin D, calcium supplement Contains both mineral and vitamins
Oil supplements Cod liver oil, primrose oil Contains oil base, with vit, minerals
Vitamins Vitamin C, vitamin B Contains only vitamin
Presentation Title: Dietary Supplement Health and Education Act of 1994 6
7. How are dietary supplements
regulated?
Companies must make sure that the dietary
supplements they sell are secure and correctly
identified in accordance with the Dietary
Supplement Health and Education Act
(DSHEA).
FDA does not have the authority to approve
dietary supplements or their labelling before they
are sold to the public
Presentation Title: Dietary Supplement Health and Education Act of 1994
8. Companies can often introduce a dietary supplement to the market without
notifying FDA.
FDA’s role in regulating dietary supplements primarily begins after products
enter the marketplace.
If a product is found to be unsafe or not otherwise in compliance with the law,
FDA can work with the company to bring the product into compliance or possibly
remove it from the market.
FDA regulates both finished dietary supplement products and dietary ingredients.
FDA regulates dietary supplements under a different set of regulations than those
covering "conventional" foods (edible fruits and vegetables) and drug products.
Presentation Title: Dietary Supplement Health and Education Act of 1994 8
FDA Role
9. Benefits of dietary supplements
Presentation Title: Dietary Supplement Health and Education Act of 1994 9
Probiotics- balance good
bacteria in digestive system
Vitamin D help build strong bones,
and fiber maintain bowel regularity
Ensure your body is getting
enough of proper nutrients
Provide you with better
athletic performance
Multivitamins- Healthy B.P,
essential for brain and eye health
Decrease your chances of
dealing with heart diseases
Give your immune system a
big boost
Improve physical performance
build muscle, and delay fatigue
11. Role of DSHEA
Presentation Title: Dietary Supplement Health and Education Act of 1994
11
Manufacturers and distributors of dietary supplements and dietary ingredients are
prohibited from marketing products that are adulterated or misbranded.
That means that these firms are responsible for evaluating the safety and labelling
of their products before marketing to ensure that they meet all the requirements of
the Federal Food, Drug, and Cosmetic Act (FFDCA) as amended by DSHEA and
FDA regulations.
FDA has the authority to take action against any adulterated or misbranded dietary
supplement product after it reaches the market
12. Presentation Title: Dietary Supplement Health and Education Act of 1994
12
The Dietary Supplement Health and Education Act of 1994 was enacted to
prohibit
1. Dietary supplement manufacturers and distributors from making false claims
(such as "natural" and "therapeutic," on supplement labels)
2. The law also prohibits the manufacture and sale of adulterated dietary
supplements.
Aim of these act:
1. To make dietary supplements safer by forbidding manufacturers and
distributors from producing and selling mislabelled or adulterated products.
2. Act requires that the manufacturer of the dietary supplement ensures their
product meets DSHEA and FDA regulations.
Conti...
13. Presentation Title: Dietary Supplement Health and Education Act of 1994
13
An Act To Establish Standards Regarding Dietary Supplements Under The Federal
Food, Drug, and Cosmetic Act And For Other Purposes.
Section 1
a) Short Title
Dietary Supplement Health and Education Act of 1994
b) Reference
Whenever in this Act an amendment or repeal is expressed in terms of an
amendment to, or repeal of, a section or other provision, the reference shall be
considered to be made to a section or other provision of the Federal Food, Drug,
and Cosmetic Act.
c) Table of Contents
Conti...
14. Conti...
Section 2 Findings
• The importance of nutrition and the
benefits of dietary supplements
• There is a link between the ingestion
of certain nutrients or dietary
supplements and the prevention of
chronic diseases
• Consumers should be empowered to
make choices about preventive health
care programs
• Preventive health measures, including
education, good nutrition, and
appropriate use of safe nutritional
supplements
• Promotion of good health and healthy
lifestyles improves and extends lives
• Improving the health status of United
States citizens
Presentation Title: Dietary Supplement Health and Education Act of 1994 14
15. Conti...
Section 3 Definitions
Dietary supplement
Presentation Title: Dietary Supplement Health and Education Act of 1994 15
Section 4 Safety of Dietary Supplements and Burden of Proof on FDA
The DSHEA must use either the conditions of use recommended or suggested
on the product label or, in the absence of such recommendations or
suggestions, the customary conditions of use to assess whether dietary
supplements are adulterated.
If there is insufficient knowledge to provide a reasonable assurance may be
determined to be adulterated.
The federal government is required to provide evidence before drawing such a
determination.
16. Conti...
Section 5 Dietary Supplement Claims
Dietary Supplement Labeling Exemptions
A. In General: A publication, including an article, a chapter in a book, or an official
abstract of a peer-reviewed scientific publication that appears in an article and
was prepared by the author or the editors of the publication, which is reprinted in
its entirety, shall not be defined as labeling.
Used in connection with marketing of dietary supplements to consumers when it is...
• Is not false or misleading
• Does not promote a particular manufacturer or brand of a dietary supplement
• Is displayed or presented with other such items on the same subject matter
Presentation Title: Dietary Supplement Health and Education Act of 1994 16
17. Presentation Title: Dietary Supplement Health and Education Act of 1994 17
Conti...
• B. Application: Shall not apply to or in any way prevent a retailer or distributor of
dietary supplements from selling books or other publications as a part of their line of
work.
• C. Burden of proof: The burden of proving that an article or other similar matter is
inaccurate or misleading must be on the United States in any process instituted under
paragraph
Section 6 Statements of Nutritional Support
DSHEA amends the Nutrition Labeling and Education Act of 1990 (NLEA) health
claims provisions of FDCA to allow dietary supplement labels to carry any of four
types of statements of nutritional support without obtaining premarketing
authorization from FDA.
18. Presentation Title: Dietary Supplement Health and Education Act of 1994 18
Conti...
The legislation requires supplement manufacturers to have substantiation of such
label claims and to notify FDA within 30 days after first marketing a product with a
statement of nutritional support that such a statement is being made.
The label must also carry a disclaimer “prominently displayed and in boldface type”
that states:
This statement has not been evaluated by the Food and Drug
Administration. This product is not intended to diagnose, treat,
cure, or prevent any disease.
19. CONTI...
Section 7 Dietary Supplement Ingredient Labeling and Nutrition Information
Labeling
Section 7 of the Act imposes specific requirements for supplement labels. It specifies some
circumstances under which dietary supplements would be misbranded. It provides that
supplement labels must list the name and quantity of each ingredient. In the case of a
proprietary blend, the “total quantity of all ingredients in the blend” may be provided.
Section 8. New Dietary Ingredients
This section describes the conditions under which a new dietary ingredient may be used in
a dietary supplement. Unless an ingredient has been “present in the food supply as an
article used for food in a form in which the food has not been chemically altered,” the
manufacturer must provide FDA with information, based on a history of use or other
evidence of safety, supporting the conclusion that the product “will reasonably be
expected to be safe.”
Presentation Title: Dietary Supplement Health and Education Act of 1994 19
20. Section 9. Good Manufacturing Practices
In addition to laying the foundation for a regulatory framework for dietary supplements
and their ingredients, DSHEA, under Section 9, provides FDA with the authority to
promulgate good manufacturing practice (GMP) regulations for supplements. The Act
stipulates that any new GMP regulations must be modelled after current food GMP
regulations and go through the required rulemaking process, allowing for public notice and
comment.
Section 10. Conforming Amendments
Section 10 of DSHEA makes changes necessary for conformance in relevant
sections of FDCA. It amends Section 201 of FDCA to provide that a food or dietary
supplement that bears a statement of nutritional support in accordance with
DSHEA is not a drug solely because the label or labeling bears such a statement.
Presentation Title: Dietary Supplement Health and Education Act of 1994 20
21. Section 11. Withdrawal of the Regulations and Notice
Under Section 11 of DSHEA, the Secretary of the Department of Health and Human
supporting the conclusion that the product Services (HHS) is directed to issue “will
reasonably be expected to be safe.” regulations rendering null and void the June This
information must be provided at least 1993 Advance Notice of Proposed 75 days before
introducing a new dietary Rulemaking (ANPR) concerning dietary ingredient into
interstate commerce. Supplements
Section 12. Commission on Dietary Supplement Labels Section 12 of DSHEA
mandates the appointment by the President of a commission to study and make
recommendations concerning label claims and statements for dietary supplements.
Section 13. Office of Dietary Supplements Section 13 of DSHEA establishes an Office
of Dietary Supplements (ODS) within the National Institutes of Health (NIH). According
to the Act, the purpose of ODS is to explore more fully the potential role of dietary
supplements as a significant part of the efforts of the United States to improve health care
and to promote scientific study of the benefits of dietary supplements
Presentation Title: Dietary Supplement Health and Education Act of 1994 21
22. Summary
The fundamental objective of the DSHEA is
to make sure that People have access to
dietary supplements that are safe and have
accurate labels.
Dietary supplements must be labelled with
particular information, such as the contents,
how much of each component is in each
serving, and the suggested daily dosing size,
according to the law.
The FDA is only permitted by law to take
action against dangerous supplements once
they are already on the market, not before
they are offered for sale to consumers.
Presentation Title: Dietary Supplement Health and Education Act of 1994 22
23. References
Presentation Title: Dietary Supplement Health and Education Act of 1994 23
1. Supplement your knowledge [Internet]. U.S. Food and Drug Administration.
FDA; [cited 2023 Apr 8]. Available from:
https://www.fda.gov/food/information-consumers-using-dietary-
supplements/supplement-your-knowledge
2. Hassan S, Egbuna C, Tijjani H, Ifemeje JC, Olisah MC, Patrick-Iwuanyanwu
KC, Onyeike PC, Ephraim-Emmanuel BC. Dietary supplements: Types, health
benefits, industry and regulation. Functional Foods and Nutraceuticals:
Bioactive Components, Formulations and Innovations. 2020:23-38.
3. Dietary supplements [Internet]. U.S. Food and Drug Administration. FDA;
[cited 2023 Apr 8]. Available from: https://www.fda.gov/food/dietary-
supplements
24. Presentation Title: Dietary Supplement Health and Education Act of 1994 24
3. Dietary Supplement Health and Education Act (DSHEA) [Internet].
Painscale.com. [cited 2023 Apr 8]. Available from:
https://www.painscale.com/article/dietary-supplement-health-and-education-
act-dshea
4. Nesheim MC, Dickinson A, Shiriki K, Farnsworth NR, Gilhooley M,
Associates LLBP, et al. MEMBERSHIP OF THE COMMISSION ON
DIETARY SUPPLEMENT LABELS chair [Internet]. Nih.gov. [cited 2023 Apr
8]. Available from: https://ods.od.nih.gov/pubs/DSHEA1997report.pdf
5. FDA 101: Dietary supplements [Internet]. U.S. Food and Drug Administration.
FDA; [cited 2023 Apr 8]. Available from:
https://www.fda.gov/consumers/consumer-updates/fda-101-dietary-
supplements.
References...